{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:34:22Z","timestamp":1785490462600,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":101,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004165","name":"Stop! Children's Cancer of Palm Beach County","doi-asserted-by":"publisher","award":["MR\/K01532X\/1"],"award-info":[{"award-number":["MR\/K01532X\/1"]}],"id":[{"id":"10.13039\/100004165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT091663MA"],"award-info":[{"award-number":["WT091663MA"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI082630"],"award-info":[{"award-number":["U19AI082630"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004211","name":"Oxford Martin School, University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.antiviral.2017.08.016","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T19:46:53Z","timestamp":1503604013000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing"],"prefix":"10.1016","volume":"146","author":[{"given":"Meike H.","family":"van der Ree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Stelma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie B.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-6715","authenticated-orcid":false,"given":"Leo","family":"Swadling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"van der Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan J.","family":"Sinnige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad C.","family":"van Nuenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Marleen L.","family":"de Vree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-9161","authenticated-orcid":false,"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje A.","family":"Kootstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik W.","family":"Reesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.08.016_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2017.08.016_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/597072","article-title":"Cellular immune responses during high-dose interferon-\u03b1 induction therapy for hepatitis C virus infection","volume":"199","author":"Barnes","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.08.016_bib3","doi-asserted-by":"crossref","first-page":"e1000947","DOI":"10.1371\/journal.ppat.1000947","article-title":"Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation","volume":"6","author":"Bengsch","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2017.08.016_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/jvh.12465","article-title":"Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals","volume":"22","author":"Burchill","year":"2015","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2017.08.016_bib5","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.27278","article-title":"T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee","volume":"60","author":"Callendret","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.08.016_bib6","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1158\/0008-5472.CAN-08-4797","article-title":"MiR-122\/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells","volume":"69","author":"Fornari","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2017.08.016_bib7","first-page":"3343","article-title":"Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct","volume":"60","author":"Gordon","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2017.08.016_bib8","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1158\/0008-5472.CAN-06-4607","article-title":"Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma","volume":"67","author":"Gramantieri","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2017.08.016_bib9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.08.016_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/eji.201444686","article-title":"Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes","volume":"45","author":"Kelly","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.antiviral.2017.08.016_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni1241","article-title":"T\u00a0cells and viral persistence: lessons from diverse infections","volume":"6","author":"Klenerman","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2017.08.016_bib12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/jvh.12075","article-title":"Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy","volume":"20","author":"K\u00f6berle","year":"2013","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2017.08.016_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.08.016_bib14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2016.12.019","article-title":"Increased peripheral cd4+ regulatory t cells persist after successful direct-acting antiviral treatment of chronic hepatitis C","volume":"66","author":"Langhans","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2017.08.016_bib15","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.08.016_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2008.07.154","article-title":"miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines","volume":"375","author":"Lin","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2017.08.016_bib17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-specific CD8+ T cell function by interferon-free therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2017.08.016_bib18","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN-free HCV Treatment outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.antiviral.2017.08.016_bib19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.08.016_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In\u00a0vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.08.016_bib21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.antiviral.2017.08.016_bib22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.08.016_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/infdis\/jiv391","article-title":"Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment","volume":"213","author":"Spaan","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.08.016_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29148","article-title":"Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101","author":"Stelma","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.08.016_bib25","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/hep.22806","article-title":"MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma","volume":"49","author":"Tsai","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.08.016_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hep.21242","article-title":"Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses","volume":"44","author":"Urbani","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.08.016_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvh.12001","article-title":"Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122","volume":"20","author":"van der Meer","year":"2013","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2017.08.016_bib28","first-page":"1","article-title":"Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial","volume":"6736","author":"van der Ree","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.08.016_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apt.13432","article-title":"Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma","volume":"43","author":"van der Ree","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2017.08.016_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/jvh.12470","article-title":"Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir\/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects","volume":"23","author":"Waring","year":"2016","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2017.08.016_bib31","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2017.08.016_bib32","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.23875","article-title":"A\u00a0novel GSK-3 beta-C\/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma","volume":"52","author":"Zeng","year":"2010","journal-title":"Hepatology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730390X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730390X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:23Z","timestamp":1759062443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421730390X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":32,"alternative-id":["S016635421730390X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.08.016","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}